A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Margaret E Tome, David B F Johnson, Lisa M Rimsza, Robin A. Roberts, Thomas M. Grogan, Thomas P Miller, Larry W. Oberley, Margaret M Briehl

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in which approximately 40% of the patients respond well to current chemotherapy, but the prognosis for the other 60% is poor. The Leukemia/Lymphoma Molecular Profiling Project (LLMPP) used microarray technology to define a molecular profile for each of 240 patients with DLBCL and develop a molecular outcome predictor score that accurately predicted patient survival. Data from our laboratory and others suggest that alterations in antioxidant defense enzyme levels and redox environment can be oncogenic and affect the response to glucocorticoid treatment, one of the components of combination chemotherapy regimens for lymphoma. The goal of the current study was to reanalyze the LLMPP microarray data to determine whether the levels of antioxidant defense enzymes and redox proteins were correlated with prognosis in DLBCL. We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity. The data suggest that the patients with the worst prognosis combine a decrease in antioxidant defense enzyme expression with an increase in thioredoxin system function (the redox signature score).

Original languageEnglish (US)
Pages (from-to)3594-3601
Number of pages8
JournalBlood
Volume106
Issue number10
DOIs
StatePublished - Nov 15 2005

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Oxidation-Reduction
Thioredoxins
Chemotherapy
Antioxidants
Cells
Microarrays
Enzymes
Lymphoma
Glutathione Peroxidase
Leukemia
Catalase
Glucocorticoids
Superoxide Dismutase
Proteins
Combination Drug Therapy
Technology
Drug Therapy
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. / Tome, Margaret E; Johnson, David B F; Rimsza, Lisa M; Roberts, Robin A.; Grogan, Thomas M.; Miller, Thomas P; Oberley, Larry W.; Briehl, Margaret M.

In: Blood, Vol. 106, No. 10, 15.11.2005, p. 3594-3601.

Research output: Contribution to journalArticle

Tome, Margaret E ; Johnson, David B F ; Rimsza, Lisa M ; Roberts, Robin A. ; Grogan, Thomas M. ; Miller, Thomas P ; Oberley, Larry W. ; Briehl, Margaret M. / A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. In: Blood. 2005 ; Vol. 106, No. 10. pp. 3594-3601.
@article{2b3ad8f638724edb8d9f7ab4ee18e029,
title = "A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in which approximately 40{\%} of the patients respond well to current chemotherapy, but the prognosis for the other 60{\%} is poor. The Leukemia/Lymphoma Molecular Profiling Project (LLMPP) used microarray technology to define a molecular profile for each of 240 patients with DLBCL and develop a molecular outcome predictor score that accurately predicted patient survival. Data from our laboratory and others suggest that alterations in antioxidant defense enzyme levels and redox environment can be oncogenic and affect the response to glucocorticoid treatment, one of the components of combination chemotherapy regimens for lymphoma. The goal of the current study was to reanalyze the LLMPP microarray data to determine whether the levels of antioxidant defense enzymes and redox proteins were correlated with prognosis in DLBCL. We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity. The data suggest that the patients with the worst prognosis combine a decrease in antioxidant defense enzyme expression with an increase in thioredoxin system function (the redox signature score).",
author = "Tome, {Margaret E} and Johnson, {David B F} and Rimsza, {Lisa M} and Roberts, {Robin A.} and Grogan, {Thomas M.} and Miller, {Thomas P} and Oberley, {Larry W.} and Briehl, {Margaret M}",
year = "2005",
month = "11",
day = "15",
doi = "10.1182/blood-2005-02-0487",
language = "English (US)",
volume = "106",
pages = "3594--3601",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

AU - Tome, Margaret E

AU - Johnson, David B F

AU - Rimsza, Lisa M

AU - Roberts, Robin A.

AU - Grogan, Thomas M.

AU - Miller, Thomas P

AU - Oberley, Larry W.

AU - Briehl, Margaret M

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in which approximately 40% of the patients respond well to current chemotherapy, but the prognosis for the other 60% is poor. The Leukemia/Lymphoma Molecular Profiling Project (LLMPP) used microarray technology to define a molecular profile for each of 240 patients with DLBCL and develop a molecular outcome predictor score that accurately predicted patient survival. Data from our laboratory and others suggest that alterations in antioxidant defense enzyme levels and redox environment can be oncogenic and affect the response to glucocorticoid treatment, one of the components of combination chemotherapy regimens for lymphoma. The goal of the current study was to reanalyze the LLMPP microarray data to determine whether the levels of antioxidant defense enzymes and redox proteins were correlated with prognosis in DLBCL. We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity. The data suggest that the patients with the worst prognosis combine a decrease in antioxidant defense enzyme expression with an increase in thioredoxin system function (the redox signature score).

AB - Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in which approximately 40% of the patients respond well to current chemotherapy, but the prognosis for the other 60% is poor. The Leukemia/Lymphoma Molecular Profiling Project (LLMPP) used microarray technology to define a molecular profile for each of 240 patients with DLBCL and develop a molecular outcome predictor score that accurately predicted patient survival. Data from our laboratory and others suggest that alterations in antioxidant defense enzyme levels and redox environment can be oncogenic and affect the response to glucocorticoid treatment, one of the components of combination chemotherapy regimens for lymphoma. The goal of the current study was to reanalyze the LLMPP microarray data to determine whether the levels of antioxidant defense enzymes and redox proteins were correlated with prognosis in DLBCL. We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity. The data suggest that the patients with the worst prognosis combine a decrease in antioxidant defense enzyme expression with an increase in thioredoxin system function (the redox signature score).

UR - http://www.scopus.com/inward/record.url?scp=27744557376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744557376&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-02-0487

DO - 10.1182/blood-2005-02-0487

M3 - Article

C2 - 16081686

AN - SCOPUS:27744557376

VL - 106

SP - 3594

EP - 3601

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -